Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Gross Profit (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Gross Profit for 16 consecutive years, with $19.2 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 11.99% to $19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.8 million through Dec 2025, down 16.04% year-over-year, with the annual reading at $63.8 million for FY2025, 16.04% down from the prior year.
  • Gross Profit for Q4 2025 was $19.2 million at Anika Therapeutics, up from $15.6 million in the prior quarter.
  • The five-year high for Gross Profit was $29.0 million in Q2 2023, with the low at $3.8 million in Q4 2022.
  • Average Gross Profit over 5 years is $18.9 million, with a median of $19.9 million recorded in 2024.
  • The sharpest move saw Gross Profit crashed 79.18% in 2022, then soared 196.66% in 2024.
  • Over 5 years, Gross Profit stood at $18.1 million in 2021, then plummeted by 79.18% to $3.8 million in 2022, then soared by 52.93% to $5.8 million in 2023, then surged by 196.66% to $17.1 million in 2024, then grew by 11.99% to $19.2 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $19.2 million, $15.6 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.